메뉴 건너뛰기




Volumn 26, Issue 25, 2007, Pages 3637-3643

Trastuzumab: Triumphs and tribulations

Author keywords

Antineoplastic agents; Breast neoplasms; ErbB 2 receptor; Monoclonal antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; PACLITAXEL; PERTUZUMAB; SOMATOMEDIN BINDING PROTEIN; TRASTUZUMAB;

EID: 34249672864     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210379     Document Type: Review
Times cited : (288)

References (61)
  • 1
    • 33644600485 scopus 로고    scopus 로고
    • Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
    • Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N et al. (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55: 717-727.
    • (2006) Cancer Immunol Immunother , vol.55 , pp. 717-727
    • Adams, C.W.1    Allison, D.E.2    Flagella, K.3    Presta, L.4    Clarke, J.5    Dybdal, N.6
  • 2
    • 19044380618 scopus 로고    scopus 로고
    • Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    • Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI et al. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137.
    • (2002) Cancer Cell , vol.2 , pp. 127-137
    • Agus, D.B.1    Akita, R.W.2    Fox, W.D.3    Lewis, G.D.4    Higgins, B.5    Pisacane, P.I.6
  • 3
    • 33748597230 scopus 로고    scopus 로고
    • Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy
    • June 20
    • Ali SM, Esteva FJ, Fornier M, Gligorov J, Harris L, Kostler WJ et al. (2006). Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. J Clin Oncol 24(June 20 Supplement): 500.
    • (2006) J Clin Oncol , vol.24 , Issue.SUPPL.EMENT , pp. 500
    • Ali, S.M.1    Esteva, F.J.2    Fornier, M.3    Gligorov, J.4    Harris, L.5    Kostler, W.J.6
  • 4
    • 33746290773 scopus 로고    scopus 로고
    • Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
    • Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J et al. (2006). Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO 25: 3234-3244.
    • (2006) EMBO , vol.25 , pp. 3234-3244
    • Anido, J.1    Scaltriti, M.2    Bech Serra, J.J.3    Santiago Josefat, B.4    Todo, F.R.5    Baselga, J.6
  • 5
    • 31444451572 scopus 로고    scopus 로고
    • Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?
    • Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C et al. (2006). Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259-267.
    • (2006) Br J Cancer , vol.94 , pp. 259-267
    • Arnould, L.1    Gelly, M.2    Penault-Llorca, F.3    Benoit, L.4    Bonnetain, F.5    Migeon, C.6
  • 6
    • 0029991439 scopus 로고    scopus 로고
    • Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    • Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744.
    • (1996) J Clin Oncol , vol.14 , pp. 737-744
    • Baselga, J.1    Tripathy, D.2    Mendelsohn, J.3    Baughman, S.4    Benz, C.C.5    Dantis, L.6
  • 7
    • 0035169666 scopus 로고    scopus 로고
    • Mechanism of action of trastuzumab and scientific update
    • Baselga J, Albanell J, Molina MA, Arribas J. (2001). Mechanism of action of trastuzumab and scientific update. Semin Oncol 28(5 Suppl 16): 4-11.
    • (2001) Semin Oncol , vol.28 , Issue.5 SUPPL. 16 , pp. 4-11
    • Baselga, J.1    Albanell, J.2    Molina, M.A.3    Arribas, J.4
  • 8
    • 27744440126 scopus 로고    scopus 로고
    • Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
    • Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. (2005). Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16: 1772-1777.
    • (2005) Ann Oncol , vol.16 , pp. 1772-1777
    • Burstein, H.J.1    Lieberman, G.2    Slamon, D.J.3    Winer, E.P.4    Klein, P.5
  • 9
    • 20544460650 scopus 로고    scopus 로고
    • Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    • Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al. (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685.
    • (2005) J Clin Oncol , vol.23 , pp. 3676-3685
    • Buzdar, A.U.1    Ibrahim, N.K.2    Francis, D.3    Booser, D.J.4    Thomas, E.S.5    Theriault, R.L.6
  • 10
    • 0036963448 scopus 로고    scopus 로고
    • Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergisticinhibition of growth in HER2-overexpressing breast cancer cells
    • Camirand A, Lu Y, Pollak M. (2002). Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergisticinhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8: BR521-BR526.
    • (2002) Med Sci Monit , vol.8
    • Camirand, A.1    Lu, Y.2    Pollak, M.3
  • 12
    • 0032532950 scopus 로고    scopus 로고
    • NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer
    • Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ et al. (1998). NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58: 5123-5129.
    • (1998) Cancer Res , vol.58 , pp. 5123-5129
    • Christianson, T.A.1    Doherty, J.K.2    Lin, Y.J.3    Ramsey, E.E.4    Holmes, R.5    Keenan, E.J.6
  • 13
    • 0034076307 scopus 로고    scopus 로고
    • Inhibitory Fcrec eptors modulate in vivo cytotoxicity against tumor targets
    • Clynes RA, Towers TL, Presta LG, Ravetch JV. (2000). Inhibitory Fcrec eptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446.
    • (2000) Nat Med , vol.6 , pp. 443-446
    • Clynes, R.A.1    Towers, T.L.2    Presta, L.G.3    Ravetch, J.V.4
  • 14
    • 0032850677 scopus 로고    scopus 로고
    • Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastaticdisease
    • Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastaticdisease. J Clin Oncol 17: 2639-2648.
    • (1999) J Clin Oncol , vol.17 , pp. 2639-2648
    • Cobleigh, M.A.1    Vogel, C.L.2    Tripathy, D.3    Robert, N.J.4    Scholl, S.5    Fehrenbacher, L.6
  • 15
    • 0034082031 scopus 로고    scopus 로고
    • Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
    • Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A et al. (2000). Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356-2362.
    • (2000) Clin Cancer Res , vol.6 , pp. 2356-2362
    • Colomer, R.1    Montero, S.2    Lluch, A.3    Ojeda, B.4    Barnadas, A.5    Casado, A.6
  • 16
    • 0032885461 scopus 로고    scopus 로고
    • Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu
    • Cooley S, Burns LJ, Repka T, Miller JS. (1999). Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27: 1533-1541.
    • (1999) Exp Hematol , vol.27 , pp. 1533-1541
    • Cooley, S.1    Burns, L.J.2    Repka, T.3    Miller, J.S.4
  • 17
    • 33751339625 scopus 로고    scopus 로고
    • Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells
    • DiGiovanna MP, Chakraborty A. (2006). Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells. Proc Am Assoc Cancer Res 47: 1226.
    • (2006) Proc Am Assoc Cancer Res , vol.47 , pp. 1226
    • DiGiovanna, M.P.1    Chakraborty, A.2
  • 18
    • 33644528230 scopus 로고    scopus 로고
    • Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
    • Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP et al. (2005). Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7: R436-R443.
    • (2005) Breast Cancer Res , vol.7
    • Esteva, F.J.1    Cheli, C.D.2    Fritsche, H.3    Fornier, M.4    Slamon, D.5    Thiel, R.P.6
  • 19
    • 0036534121 scopus 로고    scopus 로고
    • Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    • Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L et al. (2002). Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808.
    • (2002) J Clin Oncol , vol.20 , pp. 1800-1808
    • Esteva, F.J.1    Valero, V.2    Booser, D.3    Guerra, L.T.4    Murray, J.L.5    Pusztai, L.6
  • 21
    • 4444372733 scopus 로고    scopus 로고
    • Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
    • Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E et al. (2004). Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655.
    • (2004) Clin Cancer Res , vol.10 , pp. 5650-5655
    • Gennari, R.1    Menard, S.2    Fagnoni, F.3    Ponchio, L.4    Scelsi, M.5    Tagliabue, E.6
  • 23
    • 0030944455 scopus 로고    scopus 로고
    • ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
    • Graus-Porta D, Beerli RR, Daly JM, Hynes NE. (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO 16: 1647-1655.
    • (1997) EMBO , vol.16 , pp. 1647-1655
    • Graus-Porta, D.1    Beerli, R.R.2    Daly, J.M.3    Hynes, N.E.4
  • 24
    • 0034813368 scopus 로고    scopus 로고
    • Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662
    • Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA et al. (2001). Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7: 2703-2711.
    • (2001) Clin Cancer Res , vol.7 , pp. 2703-2711
    • Hayes, D.F.1    Yamauchi, H.2    Broadwater, G.3    Cirrincione, C.T.4    Rodrigue, S.P.5    Berry, D.A.6
  • 25
    • 0037149539 scopus 로고    scopus 로고
    • Tumour biology: Herceptin acts as an anti-angiogenic cocktail
    • Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. (2002). Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280.
    • (2002) Nature , vol.416 , pp. 279-280
    • Izumi, Y.1    Xu, L.2    di Tomaso, E.3    Fukumura, D.4    Jain, R.K.5
  • 26
    • 33746867442 scopus 로고    scopus 로고
    • Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo
    • Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J et al. (2006). Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 66: 7245-7252.
    • (2006) Cancer Res , vol.66 , pp. 7245-7252
    • Jerome, L.1    Alami, N.2    Belanger, S.3    Page, V.4    Yu, Q.5    Paterson, J.6
  • 27
    • 0141787069 scopus 로고    scopus 로고
    • Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone
    • Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y et al. (2003). Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98: 1377-1385.
    • (2003) Cancer , vol.98 , pp. 1377-1385
    • Klos, K.S.1    Zhou, X.2    Lee, S.3    Zhang, L.4    Yang, W.5    Nagata, Y.6
  • 28
    • 32944461545 scopus 로고    scopus 로고
    • Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
    • Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639.
    • (2006) Cancer Res , vol.66 , pp. 1630-1639
    • Konecny, G.E.1    Pegram, M.D.2    Venkatesan, N.3    Finn, R.4    Yang, G.5    Rahmeh, M.6
  • 29
    • 3543146052 scopus 로고    scopus 로고
    • Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
    • Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, Brodowicz T. (2004). Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1618-1624.
    • (2004) Clin Cancer Res , vol.10 , pp. 1618-1624
    • Kostler, W.J.1    Schwab, B.2    Singer, C.F.3    Neumann, R.4    Rucklinger, E.5    Brodowicz, T.6
  • 30
    • 0033996361 scopus 로고    scopus 로고
    • ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
    • Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. (2000). ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20: 3210-3223.
    • (2000) Mol Cell Biol , vol.20 , pp. 3210-3223
    • Lane, H.A.1    Beuvink, I.2    Motoyama, A.B.3    Daly, J.M.4    Neve, R.M.5    Hynes, N.E.6
  • 31
    • 0038607569 scopus 로고    scopus 로고
    • The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition
    • Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R et al. (2003). The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278: 23441-23450.
    • (2003) J Biol Chem , vol.278 , pp. 23441-23450
    • XF, L.1    Claret, F.X.2    Lammayot, A.3    Tian, L.4    Deshpande, D.5    LaPushin, R.6
  • 32
    • 0029005754 scopus 로고
    • Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
    • Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H et al. (1995). Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135.
    • (1995) J Clin Oncol , vol.13 , pp. 1129-1135
    • Leitzel, K.1    Teramoto, Y.2    Konrad, K.3    Chinchilli, V.M.4    Volas, G.5    Grossberg, H.6
  • 33
    • 0025829608 scopus 로고
    • A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells
    • Lin YZ, Clinton GM. (1991). A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 6: 639-643.
    • (1991) Oncogene , vol.6 , pp. 639-643
    • Lin, Y.Z.1    Clinton, G.M.2
  • 34
    • 0346154748 scopus 로고    scopus 로고
    • Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells
    • Lu Y, Zi X, Pollak M. (2004). Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108: 334-341.
    • (2004) Int J Cancer , vol.108 , pp. 334-341
    • Lu, Y.1    Zi, X.2    Pollak, M.3
  • 35
    • 0035915421 scopus 로고    scopus 로고
    • Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
    • Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. (2001). Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857.
    • (2001) J Natl Cancer Inst , vol.93 , pp. 1852-1857
    • Lu, Y.1    Zi, X.2    Zhao, Y.3    Mascarenhas, D.4    Pollak, M.5
  • 36
    • 22344446208 scopus 로고    scopus 로고
    • Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
    • Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274.
    • (2005) J Clin Oncol , vol.23 , pp. 4265-4274
    • Marty, M.1    Cognetti, F.2    Maraninchi, D.3    Snyder, R.4    Mauriac, L.5    Tubiana-Hulin, M.6
  • 37
    • 0035874981 scopus 로고    scopus 로고
    • Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells
    • Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. (2001). Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749.
    • (2001) Cancer Res , vol.61 , pp. 4744-4749
    • Molina, M.A.1    Codony-Servat, J.2    Albanell, J.3    Rojo, F.4    Arribas, J.5    Baselga, J.6
  • 38
    • 0036187710 scopus 로고    scopus 로고
    • NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer
    • Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ et al. (2002). NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8: 347-353.
    • (2002) Clin Cancer Res , vol.8 , pp. 347-353
    • Molina, M.A.1    Saez, R.2    Ramsey, E.E.3    Garcia-Barchino, M.J.4    Rojo, F.5    Evans, A.J.6
  • 39
    • 31644439702 scopus 로고    scopus 로고
    • Herceptin: Mechanisms of action and resistance
    • Nahta R, Esteva FJ. (2006). Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138.
    • (2006) Cancer Lett , vol.232 , pp. 123-138
    • Nahta, R.1    Esteva, F.J.2
  • 40
    • 1942474587 scopus 로고    scopus 로고
    • The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
    • Nahta R, Hung MC, Esteva FJ. (2004a). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346.
    • (2004) Cancer Res , vol.64 , pp. 2343-2346
    • Nahta, R.1    Hung, M.C.2    Esteva, F.J.3
  • 41
    • 2542526069 scopus 로고    scopus 로고
    • P27 (kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells
    • Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. (2004b). P27 (kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64: 3981-3986.
    • (2004) Cancer Res , vol.64 , pp. 3981-3986
    • Nahta, R.1    Takahashi, T.2    Ueno, N.T.3    Hung, M.C.4    Esteva, F.J.5
  • 42
    • 33646712747 scopus 로고    scopus 로고
    • Mechanisms of Disease: Understanding resistance to HER2-targeted therapy in human breast cancer
    • Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. (2006). Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280.
    • (2006) Nat Clin Pract Oncol , vol.3 , pp. 269-280
    • Nahta, R.1    Yu, D.2    Hung, M.C.3    Hortobagyi, G.N.4    Esteva, F.J.5
  • 43
    • 28244432561 scopus 로고    scopus 로고
    • Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
    • Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. (2005). Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118-11128.
    • (2005) Cancer Res , vol.65 , pp. 11118-11128
    • Nahta, R.1    Yuan, L.X.2    Zhang, B.3    Kobayashi, R.4    Esteva, F.J.5
  • 44
    • 0034704870 scopus 로고    scopus 로고
    • Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
    • Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W et al. (2000). Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19: 1647-1656.
    • (2000) Oncogene , vol.19 , pp. 1647-1656
    • Neve, R.M.1    Sutterluty, H.2    Pullen, N.3    Lane, H.A.4    Daly, J.M.5    Krek, W.6
  • 46
    • 18244422222 scopus 로고    scopus 로고
    • HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
    • Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y et al. (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904.
    • (1997) J Clin Oncol , vol.15 , pp. 2894-2904
    • Press, M.F.1    Bernstein, L.2    Thomas, P.A.3    Meisner, L.F.4    Zhou, J.Y.5    Ma, Y.6
  • 47
    • 0027524245 scopus 로고
    • The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage
    • Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. (1993). The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-2923.
    • (1993) Oncogene , vol.8 , pp. 2917-2923
    • Pupa, S.M.1    Menard, S.2    Morelli, D.3    Pozzi, B.4    De Palo, G.5    Colnaghi, M.I.6
  • 49
    • 0035873815 scopus 로고    scopus 로고
    • Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    • Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A et al. (2001). Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595.
    • (2001) J Clin Oncol , vol.19 , pp. 2587-2595
    • Seidman, A.D.1    Fornier, M.N.2    Esteva, F.J.3    Tan, L.4    Kaptain, S.5    Bach, A.6
  • 50
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3    Levin, W.J.4    Ullrich, A.5    McGuire, W.L.6
  • 51
  • 52
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3    Fuchs, H.4    Paton, V.5    Bajamonde, A.6
  • 53
  • 54
    • 12344302247 scopus 로고    scopus 로고
    • Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
    • Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J et al. (2004). Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3: 1585-1592.
    • (2004) Mol Cancer Ther , vol.3 , pp. 1585-1592
    • Tanner, M.1    Kapanen, A.I.2    Junttila, T.3    Raheem, O.4    Grenman, S.5    Elo, J.6
  • 55
    • 0036467826 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    • Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
    • (2002) J Clin Oncol , vol.20 , pp. 719-726
    • Vogel, C.L.1    Cobleigh, M.A.2    Tripathy, D.3    Gutheil, J.C.4    Harris, L.N.5    Fehrenbacher, L.6
  • 56
    • 33750584030 scopus 로고    scopus 로고
    • HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: Implications for HER2-targeted antibody therapy
    • Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC et al. (2006). HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25: 6986-6996.
    • (2006) Oncogene , vol.25 , pp. 6986-6996
    • Wen, X.F.1    Yang, G.2    Mao, W.3    Thornton, A.4    Liu, J.5    Bast, R.C.6
  • 57
    • 0037068741 scopus 로고    scopus 로고
    • Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
    • Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW et al. (2002). Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263.
    • (2002) Oncogene , vol.21 , pp. 6255-6263
    • Xia, W.1    Mullin, R.J.2    Keith, B.R.3    Liu, L.H.4    Ma, H.5    Rusnak, D.W.6
  • 58
    • 30544450275 scopus 로고    scopus 로고
    • Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeuticanti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
    • Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. (2005). Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeuticanti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24: 6213-6221.
    • (2005) Oncogene , vol.24 , pp. 6213-6221
    • Xia, W.1    Gerard, C.M.2    Liu, L.3    Baudson, N.M.4    Ory, T.L.5    Spector, N.L.6
  • 59
    • 0037099532 scopus 로고    scopus 로고
    • Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action
    • Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132-4141.
    • (2002) Cancer Res , vol.62 , pp. 4132-4141
    • Yakes, F.M.1    Chinratanalab, W.2    Ritter, C.A.3    King, W.4    Seelig, S.5    Arteaga, C.L.6
  • 60
    • 0030757466 scopus 로고    scopus 로고
    • Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
    • Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S et al. (1997). Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518-2525.
    • (1997) J Clin Oncol , vol.15 , pp. 2518-2525
    • Yamauchi, H.1    O'Neill, A.2    Gelman, R.3    Carney, W.4    Tenney, D.Y.5    Hosch, S.6
  • 61
    • 0026071364 scopus 로고
    • The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, sk-br-3
    • Zabrecky JR, Lam T, McKenzie SJ, Carney W. (1991). The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, sk-br-3. J Biol Chem 266: 1716-1720.
    • (1991) J Biol Chem , vol.266 , pp. 1716-1720
    • Zabrecky, J.R.1    Lam, T.2    McKenzie, S.J.3    Carney, W.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.